Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive
leukemias. N Engl J Med. 2006;354(24):2531-2541.
Burke BA, Carroll M. BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
Leukemia. 2010;24(6):1105-1112.
López-Andrade B, Sartori F, Gutiérrez A, et al. Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion
protein. A report of two cases. Exp Hematol Oncol. 2015;5:21. doi:10.1186/s40164-016-0049-y.
Neuendorff NR, Burmeister T, Dörken B, Westermann J. BCR-ABL-positive acute myeloid leukemia: a new entity?
Analysis of clinical and molecular features. Ann Hematol. 2016;95(8):1211-1221.
Hantschel O. Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer.
2012;3(5-6):436-446.
Cuellar S, Vozniak M, Rhodes J, Forcello N, Olszta D. BCR-ABL1 tyrosine kinase inhibitors for the treatment
of chronic myeloid leukemia. J Oncol Pharm Pract. 2018;24(6):433-452.
Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to
solid tumours. Nat Rev Cancer. 2013;13(8):559-571.
Pelletier SD, Hong DS, Hu Y, Liu Y, Li S. Lack of the adhesion molecules P-selectin and intercellular
adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like
myeloproliferative disease in mice. Blood. 2004;104(7):2163-2171.
La Rosée P, O’Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens
with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a
translational perspective. Leukemia. 2002;16(7):1213-1219.